Sartorius Heads Into Q3 Results With Lenders Relaxed, Bears Quiet

SRT3 reports third-quarter results on October 22 with short sellers largely on the sidelines and the lending market comfortably loose.

The borrow picture carries almost no stress. Availability stands at 849%, meaning there are roughly eight-and-a-half shares available for every one already borrowed. That is well above the 52-week low of 674%, and borrowing costs have held near 0.68% for weeks, a level that signals no meaningful demand surge from new short-sellers. Short interest itself is a minor feature of the story: at around 1.9% of the free float, bears have made no serious commitment heading into the print. The ORTEX short score has ticked up from 32.6 to 36.9 over the past two weeks, a mild drift higher but nowhere near territory that would flag a concentrated bearish bet.

The more interesting tension sits in how Sartorius has traded relative to its peer group. The stock fell 1.4% on October 21 to close at €261.10, even as most correlated names moved the other direction. QGEN gained 5% on the day and is up more than 7% on the week. LONN and 1SXP each added around 8 to 10% over the same period. DHR and TMO, two of the sector's benchmarks, both posted modest gains. Sartorius, by contrast, has managed only a 1.2% weekly gain and remains roughly 5% below the analyst consensus price target of €272, suggesting the Street still sees room to recover but has not moved aggressively to revise targets ahead of the print. No analyst changes have been filed in the ten days before the report.

The valuation context adds nuance. Sartorius trades at 42.6x trailing earnings and 18.7x EV/EBITDA, both multiples that have crept modestly higher over the past month. The EV/EBITDA reading has actually eased slightly over seven days, down about 0.25 turns, which may reflect some caution around whether margin improvement is keeping pace with revenue recovery. The forward EPS picture is more supportive: the 12-month forward EPS growth factor scores in the 82nd percentile of the universe, and 30-day EPS momentum ranks 69th. Ownership is anchored by Bio-Rad Laboratories at 32.97% and the Sartorius family estate at 27.28%, together controlling roughly 60% of the company, so institutional flow in the free float matters more at the margin than the headline holder list suggests. Deutsche Asset Management added 142,000 shares as of the end of September, one of the more notable recent moves among institutional holders.

Looking back at recent prints, Sartorius barely moved after its July results, slipping 0.1% on the day before recovering modestly over the following week. The April print was harsher: the stock fell more than 8% on the day and extended that loss over five sessions. The question today's numbers raise is whether the recovery in the stock since April, around 20% from the trough, reflects genuine improvement in order intake and biotech customer spending, or simply a re-rating that the fundamentals still need to validate.